Investors look for signs that Skyrizi, Rinvoq can take the baton as Humira sales falter
You are here: Home / Top Stories / Earnings Outlook: AbbVie turns to newer immunology drugs as blockbuster Humira faces lower-cost competition
Market News and Views
Investors look for signs that Skyrizi, Rinvoq can take the baton as Humira sales falter